Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Flow cytometry analysis reveals upregulated integrin expression on cell surfaces following TB-500 treatment in various cell line models
Additionally, the hypothesis that elongation of telomeres equates to slowing of the aging process is notoriously hyped and furthermore depends on the supposition that circulating lymphocyte telomere length can be used as a marker for telomere length in body cells overall
Stier H, et al
doi:10.1097/AUD.0000000000000729
Organ and tissue growth concerns Because IGF-1 signaling affects cellular growth and proliferation throughout the body and not exclusively in skeletal muscle, there is concern that long-term use of IGF-1 could result in increased growth of other tissues/organs in the body
Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely
